Brii Biosciences (FRA:7SS) 3-Year Share Buyback Ratio: 0.30% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7SS Brii Biosciences Ltd FRA:7SS
33 GF Score
Price €0.10
! 1 Warning Sign
View Full Analysis

What is Brii Biosciences 3-Year Share Buyback Ratio?

Brii Biosciences FRA:7SS +2.09% 33 3-Year Share Buyback Ratio is 0.30 as of Dec. 2025. GuruFocus rates FRA:7SS with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,190 Biotechnology companies, Brii Biosciences ranks better than 94.37% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Brii Biosciences's current 3-Year Share Buyback Ratio was 0.30%.

The historical rank and industry rank for Brii Biosciences's 3-Year Share Buyback Ratio or its related term are showing as below:

FRA:7SS' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -1.1   Med: -0.75   Max: 0.3
Current: 0.3

During the past 7 years, Brii Biosciences's highest 3-Year Share Buyback Ratio was 0.30%. The lowest was -1.10%. And the median was -0.75%.

FRA:7SS's 3-Year Share Buyback Ratio is ranked better than
94.37% of 1190 companies
in the Biotechnology industry
Industry Median: -11.75 vs FRA:7SS: 0.30

Brii Biosciences (FRA:7SS) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Brii Biosciences 3-Year Share Buyback Ratio Related Terms


FRA:7SS vs VRTX, REGN, RVMD: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Brii Biosciences's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brii Biosciences 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brii Biosciences's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Brii Biosciences's 3-Year Share Buyback Ratio falls into.


FRA:7SS
33GF Score
Brii Biosciences Ltd FRA:7SS
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brii Biosciences 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of 0.30 mean?
Brii Biosciences (FRA:7SS) has a 3-Year Share Buyback Ratio of 0.30 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Brii Biosciences and its competitors. According to the industry distribution chart, Brii Biosciences ranks #67 out of 1190 companies in the Biotechnology industry, placing it in the top 5.6%.
Is Brii Biosciences' 3-Year Share Buyback Ratio too high?
Brii Biosciences' current 3-Year Share Buyback Ratio is 0.30. Based on the distribution chart, Brii Biosciences ranks #67 out of 1190 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Brii Biosciences has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Brii Biosciences' 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Brii Biosciences ranks #67 out of 1190 companies for 3-Year Share Buyback Ratio. This places Brii Biosciences in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Brii Biosciences and its competitors. Brii Biosciences's current 3-Year Share Buyback Ratio is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brii Biosciences stock overvalued right now?
Brii Biosciences (FRA:7SS) has a current 3-Year Share Buyback Ratio of 0.30. The current 3-Year Share Buyback Ratio is 0.30. Brii Biosciences' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Brii Biosciences (FRA:7SS), the current 3-Year Share Buyback Ratio is 0.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brii Biosciences Business Description

Address No. 1 North Yongtaizhuang Road, 3rd Floor, Building 7, Zhongguancun Dongsheng, International Science Park, Haidian District, Beijing, CHN, 100192
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
33GF Score

Get the complete analysis for FRA:7SS

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.10
Price